Meeting
2021 Gastrointestinal Cancers Symposium
AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study.
Authors
Wangshu Dai
The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China
Wangshu Dai , Xin Qiu , Changchang Lu , Changchang Lu , Zhengyun Zou , Huizi Sha , Weiwei Kong , Baorui Liu , Juan Du
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT0376867
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 384)
DOI
10.1200/JCO.2021.39.3_suppl.384
Abstract #
384
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.
First Author: Fabienne Portales
Poster
2014 Gastrointestinal Cancers Symposium
Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.
First Author: Yue Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2023 ASCO Annual Meeting
Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).
First Author: Inna Markovna Chen